1月25日,据《华尔街日报》周日报道,默沙东公司已终止关于收购抗癌药研发企业Revolution Medicines的相关磋商。该报援引知情人士消息称,双方因未能就收购价格达成共识,相关商谈就此搁置。不过,并不排除后续重启磋商,或者有其他竞购方参与角逐Revolution Medicines的可能性。目前,上述报道尚未得到核实。由于处于非工作时间,默沙东与Revolution Medicines均...
Source Link1月25日,据《华尔街日报》周日报道,默沙东公司已终止关于收购抗癌药研发企业Revolution Medicines的相关磋商。该报援引知情人士消息称,双方因未能就收购价格达成共识,相关商谈就此搁置。不过,并不排除后续重启磋商,或者有其他竞购方参与角逐Revolution Medicines的可能性。目前,上述报道尚未得到核实。由于处于非工作时间,默沙东与Revolution Medicines均...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.